WallStreetZenWallStreetZen

NASDAQ: RNAZ
Transcode Therapeutics Inc Earnings & Revenue

RNAZ earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$19.6M
Current Profit Margin
0%

RNAZ Return on Equity

Current Company
-821.8%
Current Industry
15.4%
Current Market
-8.4%
RNAZ's Return on Equity (-821.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RNAZ announces earnings.

RNAZ Return on Assets

Current Company
-267.6%
Current Industry
2.2%
RNAZ is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RNAZ Return on Capital Employed

Current Company
-423.2%
Current Industry
17.7%

RNAZ vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RNAZ$0.00-$19.19M-$19.59MN/AN/A
GRI$0.00-$11.97M-$12.86M-100.00%N/A
TCBP$3.48M-$1.45M-$1.89M+49.78%N/A
SPRC$829.75k$539.75k-$71.75kN/A-68.32%
BDRX$359.04k-$4.25M-$4.30M-23.29%N/A

Transcode Therapeutics Earnings & Revenue FAQ

What were RNAZ's earnings last quarter?

On Invalid Date, Transcode Therapeutics (NASDAQ: RNAZ) reported Q3 2023 earnings per share (EPS) of -$67.20, up 74.58% year over year. Total Transcode Therapeutics earnings for the quarter were -$5.30 million. In the same quarter last year, Transcode Therapeutics's earnings per share (EPS) was -$264.40.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.

What was RNAZ's earnings growth in the past year?

As of Q1 2024, Transcode Therapeutics's earnings has grown year over year. Transcode Therapeutics's earnings in the past year totalled -$19.59 million.

What was RNAZ's revenue last quarter?

On Invalid Date, Transcode Therapeutics (NASDAQ: RNAZ) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Transcode Therapeutics's revenue was $0.00.

What was RNAZ's revenue growth in the past year?

As of Q1 2024, Transcode Therapeutics's revenue has grown null year over year. Transcode Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.